Renal & Urology News9d
Emblaveo Approved for Intra-Abdominal Infections in Patients With Limited Options
for patients 18 years and older who have limited or no alternative options for the treatment of complicated intra-abdominal infections (cIAI), including those caused by the following susceptible ...
US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections
AbbVie said that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections on Friday. AbbVie and co-developer Pfizer's drug, Emblaveo, is approved in ...
Hosted on MSN13d
FDA approves AbbVie’s Emblaveo for intra-abdominal infections
AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...
Healio16d
FDA approves Emblaveo for complicated intra-abdominal infections
The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options. Emblaveo (aztreonam and avibactam), is the first ...
Contract Pharma13d
AbbVie’s EMBLAVEO Approved by FDA for Treatment of Complicated Intra-Abdominal Infections
Addresses the significant threat of antimicrobial resistance.
Pharm Exec12d
FDA Approves AbbVie’s Emblaveo for Complicated Intra-Abdominal Infections
Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be approved by the FDA for complicated intra-abdominal infections with limited ...